The Claim

Plasma p-tau217 levels above 0.471 pg/mL are strongly associated with amyloid-beta positivity on PET scans in adults aged 75.8 years with high cerebrovascular disease burden, with a positive predictive value of 82% and an area under the curve of 0.923, indicating high diagnostic accuracy for identifying Alzheimer's-related brain pathology in populations with vascular comorbidities.

Source: Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
44score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In adults aged approximately 76 with significant blood vessel disease in the brain, a blood biomarker called p-tau217 above 0.471 pg/mL consistently correlates with the presence of amyloid-beta plaques detected by PET imaging, with 82% accuracy in identifying those with amyloid pathology.

See the scientific wording

Plasma p-tau217 levels above 0.471 pg/mL are strongly associated with amyloid-beta positivity on PET scans in adults aged 75.8 years with high cerebrovascular disease burden, with a positive predictive value of 82% and an area under the curve of 0.923, indicating high diagnostic accuracy for identifying Alzheimer's-related brain pathology in populations with vascular comorbidities.

Why this might work

When amyloid plaques build up in the brain, they trigger a chain reaction in nerve cells that causes a specific protein called tau to change shape and pick up extra phosphate groups at one spot. This altered tau leaks into the blood, and when its level crosses a certain threshold, it reliably signals that amyloid plaques are present in the brain.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease

    In older people with blood vessel problems in the brain, a simple blood test that measures p-tau217 can correctly identify who has Alzheimer’s plaques 82% of the time — just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.